<DOC>
	<DOCNO>NCT00428558</DOCNO>
	<brief_summary>Core binding factor ( CBF ) acute myeloid leukemia ( AML ) include AMLs carry ( 8 ; 21 ) translocation well AMLs carry either inversion chromosome 16 translocation ( 16 ; 16 ) . CBF-AMLs characterized high sensitivity standard chemotherapeutical agent , especially cytarabine administer high-dose bolus infusion , thus relative good prognosis . However , relapse rate still comprise 30 50 % patient , even overall survival may reach approximately 65 % due potential salvage late relapse . The primary purpose protocol compare two modality timed-sequential induction order improve result treatment CBF-AML patient . This protocol also include biological characterization heterogeneity disease ( gene mutation transcription profile ) , well centralize minimal residual disease monitor centralized evaluation pharmacogenetic polymorphism .</brief_summary>
	<brief_title>Timed-Sequential Induction CBF-AML</brief_title>
	<detailed_description>Core binding factor ( CBF ) acute myeloid leukemia ( AML ) include AMLs carry ( 8 ; 21 ) translocation well AMLs carry either inversion chromosome 16 translocation ( 16 ; 16 ) . CBF-AMLs characterized high sensitivity standard chemotherapeutical agent , especially cytarabine administer high-dose bolus infusion , thus relative good prognosis . However , relapse rate still comprise 30 50 % patient , even overall survival may reach approximately 65 % due potential salvage late relapse . Initial high white blood cell count , activate mutation cKit , Ras , FLT3 gene , persistence high minimal residual disease ( MRD ) level ( evidence AML1-ETO CBFb-MYH11 specific RQ-PCR tool ) main bad-prognostic factor patient CBF-AML . This project include new single French protocol treat patient CBF-AML represent approximately 15 % AML patient . This common protocol elaborate two main French cooperative group adult AML ( ALFA GOELAMS ) . In addition unique specific therapeutical strategy , protocol include biological characterization heterogeneity disease ( gene mutation transcription profile ) , well centralize MRD monitor centralized evaluation pharmacogenetic polymorphism . This project well-positioned international competition , use many platform POLECANCER follow objective : 1 ) improve result treatment CBF-AML patient ; 2 ) organize French clinical biological network CBF-AML aim test new target therapeutical agent ( tyrosine kinase and/or farnesyl transferase inhibitor ) next future . TREATMENT DESIGN Induction course Systematic timed-sequential induction ( arm A ) DAUNORUBICINE ( DNR ) : 60 mg/m2/day IV ( 30 min ) , Day 1 , 2 , 3 CYTARABINE ( AraC ) : 500 mg/m2/day Continuous infusion , Day 1 3 DAUNORUBICINE ( DNR ) : 35 mg/m2/day IV ( 30 min ) , Day 8 9 CYTARABINE ( AraC ) : 1 gr/m2/12 h IV ( 2h ) , Day 8 , 9 , 10 Response-adapted timed-sequential induction ( arm G ) DAUNORUBICINE ( DNR ) : 60 mg/m2/dayIV ( 30 min ) , Day 1 , 2 , 3 CYTARABINE ( AraC ) : 200 mg/m2/dayContinuous infusion , Day 1 7 Peripheral blood bone marrow evaluation Day 15 . The following second induction course administer patient persistent marrow disease Day 15 : DAUNORUBICINE ( DNR ) : 35 mg/m2/day IV ( 30 min ) , Day 16 17 CYTARABINE ( AraC ) 1 gr/m2/12 h IV ( 2h ) , Day 16 , 17 , 18 Persistent marrow disease Day 15 define 10 % leukemic blast non aplastic non hypoplastic bone marrow aspiration sample . Salvage course In patient reach CR first induction course ( either SI TSI ) , salvage course administer . Salvage therapy initiate Day 35 arm A Day 42 arm G. CYTARABINE ( AraC ) :3 gr/m2/12h IV ( 2h ) , Day 1 , 3 , 5 , 7 AMSACRINE : 100 mg/m2/day IV ( 30 min ) , Day 5 7 G-CSF lenograstim : Day 8 myeloid recovery ( &gt; 500 PMN/µL ) Consolidation cycle Three monthly cycle consolidation administer patient reach hematological CR induction induction + salvage . CYTARABINE ( AraC ) : 3 g/m2/12h IV ( 2h ) , Day 1 , 3 , 5 G-CSF lenograstim : Day 8 myeloid recovery ( &gt; 500 PMN/µL )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients age 1860 year . With newlydiagnosed de novo therapyrelated CBFAML define No previously treat antileukemic agent . No present diagnosis uncontrolled metastatic tumor . OMS performance status &lt; 2 , Absence uncontrolled severe infection , AST ALT 2.5 x ULN , Total bilirubin 1.5 x ULN , Serum creatinine 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>Core Binding Factor</keyword>
	<keyword>( 8 ; 21 )</keyword>
	<keyword>inv ( 16 )</keyword>
	<keyword>timed-sequential induction</keyword>
</DOC>